Article
Biochemistry & Molecular Biology
Barbara Bellei, Silvia Caputo, Emilia Migliano, Gianluca Lopez, Valeria Marcaccini, Carlo Cota, Mauro Picardo
Summary: The study showed that the molecule Onco-P20, a combination of paclitaxel and hyaluronic acid, targets cells expressing high levels of CD44 and induces apoptotic cell death in sensitive carcinoma cells while causing growth arrest and gene expression changes in less sensitive fibroblasts. Onco-P20-treated fibroblasts exhibited reduced growth factor production, downmodulation of the Wnt signaling pathway, and acquired a pro-inflammatory profile, leading to reduced proliferation rate of carcinoma cells in their presence. Fibroblasts from skin cancer lesions also displayed anti-neoplastic activity under Onco-P20 treatment, suggesting it as a potential alternative therapy for NMSC.
Review
Oncology
Anna Maxi Wandmacher, Anne-Sophie Mehdorn, Susanne Sebens
Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest tumors commonly diagnosed at advanced stages, characterized by tumor heterogeneity at multiple levels. This tumor heterogeneity, along with the impact of the tumor microenvironment and altered microbiome of PDAC patients, plays diverse effects on the development, progression, and therapy responses of PDAC. Understanding and considering this multi-level heterogeneity is crucial for developing novel therapeutic concepts to potentially improve the situation of PDAC patients.
Review
Cell Biology
Ester Pfeifer, Joy M. Burchell, Francesco Dazzi, Debashis Sarker, Richard Beatson
Summary: PDAC is associated with poor prognosis due to advanced stage at diagnosis and aggressive tumor biology. Efforts to target CAF, a predominant cell type in the tumor microenvironment, have shown disappointing results in clinical trials.
Review
Oncology
Tomohiko Shinkawa, Kenoki Ohuchida, Masafumi Nakamura
Summary: Stroma-targeting therapy in pancreatic ductal adenocarcinoma (PDAC) has been extensively studied, but no effective candidates have been found yet. Cancer-associated fibroblasts (CAFs) have been traditionally considered tumor-promoting, but recent studies suggest the existence of tumor-suppressive CAF subtypes. Single-cell RNA sequencing has revealed the heterogeneity within the tumor microenvironment of PDAC, including CAFs and tumor immunity. The clarification of this heterogeneity is urgently needed to develop effective therapeutic strategies for PDAC.
Review
Oncology
Jonathan Robert Weitz, Herve Tiriac, Tatiana Hurtado de Mendoza, Alexis Wascher, Andrew M. Lowy
Summary: Pancreatic ductal adenocarcinoma (PDAC) has the highest mortality rate among major cancers, and current therapies have had limited success. Understanding the complex tumor microenvironment (TME) of PDAC, including fibrotic matrix and immunosuppressive features, is crucial for developing effective treatments. Organotypic tumor slices from patient tumors provide a valuable model system to study TME interactions and potential therapeutic approaches for personalized cancer therapy.
Review
Pathology
Mara H. Sherman, Gregory L. Beatty
Summary: Pancreatic ductal adenocarcinoma (PDAC) has a diverse stromal microenvironment that plays a significant role in disease biology and treatment resistance. Recent advancements in imaging, single-cell analytics, and disease modeling have provided insights into the complexity of PDAC tumors. Understanding the functional and spatial dependencies between cancer cells and extracellular matrix components can reveal therapeutic vulnerabilities.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE
(2023)
Review
Oncology
Friederike V. Opitz, Lena Haeberle, Alexandra Daum, Irene Esposito
Summary: PDAC is an aggressive tumor with poor prognosis, mainly due to late detection. The tumor microenvironment (TME) plays a crucial role in PDAC development, including cancer-associated fibroblasts, immunosuppressive immune cells, and immunoregulatory factors. Understanding the composition of TME in early stages is important for improving treatment strategies for PDAC.
Article
Biochemistry & Molecular Biology
Chonghui Hu, Renpeng Xia, Xiang Zhang, Tingting Li, Yuancheng Ye, Guolin Li, Rihua He, Zhihua Li, Qing Lin, Shangyou Zheng, Rufu Chen
Summary: This study found that the CAF-specific circRNA circFARP1 plays a critical role in pancreatic ductal adenocarcinoma (PDAC), and is associated with gemcitabine resistance and poor patient survival. Mechanistically, circFARP1 regulates the interaction between CAV1, ZNRF1, and LIF, influencing the development of tumor cell stemness and drug resistance. Additionally, high levels of circFARP1 are associated with elevated serum LIF levels and poor patient survival in PDAC.
Article
Oncology
Tomohiko Shinkawa, Kenoki Ohuchida, Yuki Mochida, Kukiko Sakihama, Chika Iwamoto, Toshiya Abe, Noboru Ideno, Yusuke Mizuuchi, Koji Shindo, Naoki Ikenaga, Taiki Moriyama, Kohei Nakata, Yoshinao Oda, Masafumi Nakamura
Summary: The presence of abundant stroma in pancreatic ductal adenocarcinoma (PDAC) can define the PDAC phenotype and induce distinct therapeutic responses. Cancer-associated fibroblasts (CAFs) maintain the differentiated PDAC phenotype through secreting niche factors and induce different drug responses.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Cell Biology
James A. McCubrey, Li Yang, Stephen L. Abrams, Linda S. Steelman, Matilde Y. Follo, Lucio Cocco, Stefano Ratti, Alberto M. Martelli, Giuseppa Augello, Melchiorre Cervello
Summary: This review discusses the roles of TP53 and miRs in the PDAC tumor microenvironment and how mutated TP53 and loss of miR expression contribute to tumor progression.
Article
Biochemistry & Molecular Biology
Natalia Guillen Diaz-Maroto, Gemma Garcia-Vicien, Giovanna Polcaro, Maria Banuls, Nerea Albert, Alberto Villanueva, David G. Mollevi
Summary: This study demonstrates that IL1 beta secreted by cancer cells can alter the characteristics of surrounding normal fibroblasts, giving them protumorogenic features, particularly tolerance to cytotoxic drugs. This finding highlights the role of IL1 beta in promoting tumor cell development within the tumor microenvironment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Woosol Chris Hong, Da Eun Lee, Hyeon Woong Kang, Myeong Jin Kim, Minsoo Kim, Ju Hyun Kim, Sungsoon Fang, Hyo Jung Kim, Joon Seong Park
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly form of pancreatic cancer and the role of CD74 in PDAC is not well understood. Silencing CD74 in the pancreatic cancer cell line Capan-1 led to reduced cell proliferation, migration, invasion, increased apoptosis, and decreased expression and secretion of S100A8 and S100A9. The study suggests that CD74 may serve as a potential diagnostic biomarker and therapeutic target for pancreatic cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Cell Biology
Marlene Geyer, Karla Queiroz
Summary: PDAC, the most common type of pancreatic cancer, is characterized by early metastasis and often requires chemotherapy treatment. With only 20% of tumors resectable, there is an urgent need for innovative modeling platforms to better understand and treat this complex disease.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Bala Prabhakar Girish, Begum Dariya, Mastan Mannarapu, Ganji Purnachandra Nagaraju, Ganji Seeta Rama Raju
Summary: Pancreatic cancer faces challenges from abnormal proliferation of stromal cells, and traditional treatments may cause excessive toxicity to normal cells. Nanotechnology can deliver drugs directly to tumor sites, enhancing treatment efficacy.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Cell Biology
Aaron Galindo-Vega, Vilma Maldonado-Lagunas, Irma B. Mitre-Aguilar, Jorge Melendez-Zajgla
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy due to a complex tumor microenvironment and the presence of cancer stem cells, which contribute to therapy resistance and tumor relapse. Understanding and targeting the tumor microenvironment and cancer stem cells may be crucial for effective PDAC therapies. This review summarizes recent advances in the role of tumor microenvironment in pancreatic neoplastic progression.
Article
Oncology
Michael A. James, William L. Seibel, Elena Kupert, Xiao X. Hu, Vishwakanth Y. Potharla, Marshall W. Anderson
Article
Biochemistry & Molecular Biology
Yongik Lee, Yian Wang, Michael James, Joseph H. Jeong, Ming You
MOLECULAR CARCINOGENESIS
(2016)
Article
Biochemistry & Molecular Biology
Rachel Lieberman, Donghai Xiong, Michael James, Younghun Han, Christopher I. Amos, Liang Wang, Ming You
MOLECULAR CARCINOGENESIS
(2016)
Article
Oncology
Laszlo G. Puskas, Imola Man, Gabor Szebeni, Laszlo Tiszlavicz, Susan Tsai, Michael A. James
MOLECULAR CANCER THERAPEUTICS
(2016)
Article
Plant Sciences
Christopher R. Bodle, Duncan I. Mackie, Michael P. Hayes, Josephine H. Schamp, Michael R. Miller, Michael D. Henry, Jonathan A. Doom, Jon C. D. Houtman, Michael A. James, David L. Roman
JOURNAL OF NATURAL PRODUCTS
(2017)
Article
Oncology
Yan Lu, Pengyuan Liu, Francoise Van den Bergh, Victoria Zellmer, Michael James, Weidong Wen, Clinton J. Grubbs, Ronald A. Lubet, Ming You
CANCER PREVENTION RESEARCH
(2012)
Article
Oncology
Michael A. James, Haris G. Vikis, Everett Tate, Amy L. Rymaszewski, Ming You
Article
Oncology
Pengyuan Liu, Carl Morrison, Liang Wang, Donghai Xiong, Peter Vedell, Peng Cui, Xing Hua, Feng Ding, Yan Lu, Michael James, John D. Ebben, Haiming Xu, Alex A. Adjei, Karen Head, JaimeW. Andrae, Michael R. Tschannen, Howard Jacob, Jing Pan, Qi Zhang, Francoise Van den Bergh, Haijie Xiao, Ken C. Lo, Jigar Patel, Todd Richmond, Mary-Anne Watt, Thomas Albert, Rebecca Selzer, Marshall Anderson, Jiang Wang, Yian Wang, Sandra Starnes, Ping Yang, Ming You
Article
Biochemistry & Molecular Biology
Michael A. James, Huijing Fu, Yan Liu, Da-Ren Chen, Ming You
MOLECULAR CARCINOGENESIS
(2011)
Article
Genetics & Heredity
Matthew L. Freedman, Alvaro N. A. Monteiro, Simon A. Gayther, Gerhard A. Coetzee, Angela Risch, Christoph Plass, Graham Casey, Mariella De Biasi, Chris Carlson, David Duggan, Michael James, Pengyuan Liu, Jay W. Tichelaar, Haris G. Vikis, Ming You, Ian G. Mills
Article
Multidisciplinary Sciences
Michael A. James, Weidong Wen, Yian Wang, Lauren A. Byers, John V. Heymach, Kevin R. Coombes, Luc Girard, John Minna, Ming You
Article
Oncology
William R. Clarke, Laufey Amundadottir, Michael A. James
INTERNATIONAL JOURNAL OF CANCER
(2019)
Article
Biochemistry & Molecular Biology
Fankai Xiao, Peng Zhang, Yuan Wang, Yijun Tian, Michael James, Chiang-Ching Huang, Lidong Wang, Liang Wang
MOLECULAR CARCINOGENESIS
(2020)
Article
Oncology
Deepak Parashar, Anjali Geethadevi, Donna McAllister, Johnathan Ebben, Francis C. Peterson, Davin R. Jensen, Erin Bishop, Sunila Pradeep, Brian F. Volkman, Michael B. Dwinell, Pradeep Chaluvally-Raghavan, Michael A. James
Summary: Recurrence of therapy-resistant tumors remains a major challenge in the field of solid tumor oncology, particularly in ovarian and pancreatic cancer. High expression of CLPTM1L in ovarian tumor cells is associated with poor prognosis, and inhibiting CLPTM1L can re-sensitize resistant ovarian cancer cells to platinum-based therapy. Additionally, CLPTM1L can confer intercellular resistance to chemotherapeutic killing in an ectodomain-dependent manner, which can be blocked by anti-CLPTM1L biologics.
NPJ PRECISION ONCOLOGY
(2021)